Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 06/25–06/26 | 06/26 | 11,156 sh2 trades | $3.04avg. | $33,919.45 | −9.5% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 06/22–06/23 | 06/24 | 11,444 sh2 trades | $3.48avg. | $39,829.25 | −8.9% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 06/16–06/17 | 06/18 | 4,126 sh2 trades | $3.18avg. | $13,110.42 | −3.1% | |
Cadrenal TherapeuticsCVKD | Open-market sale | 06/11–06/15 | 06/15 | 18,124 sh3 trades | $3.88avg. | $70,351.96 | −12.0% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 06/08–06/10 | 06/10 | 22,385 sh3 trades | $4.17avg. | $93,293.86 | −12.9% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 06/03–06/05 | 06/05 | 8,285 sh3 trades | $4.37avg. | $36,209.04 | −4.6% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 05/29–06/02 | 06/02 | 652 sh2 trades | $4.72avg. | $3,074.57 | −0.4% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 05/11–05/28 | 05/29 | 12,763 sh3 trades | $5.44avg. | $69,450.97 | −6.5% | |
Quang X. PhamCEO and Chairman | Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 05/22 | 05/26 | 1,165 sh | $5.69 | $6,628.85 | −0.6% |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/12/29 | 25/12/31 | 9,933 sh | $6.97 | $69,233.01 | −100.0% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/10/24–25/10/27 | 25/10/28 | 3,600 sh2 trades | $13.99avg. | $50,364 | −26.6% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/10/24–25/10/27 | 25/10/28 | 2,444 sh2 trades | $14.01avg. | $34,236.72 | −1.2% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/10/09–25/10/13 | 25/10/14 | 3,493 sh2 trades | $14.03avg. | $49,011.07 | −20.5% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/10/09–25/10/13 | 25/10/14 | 3,600 sh2 trades | $14.09avg. | $50,706 | −1.8% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/10/06 | 25/10/07 | 107 sh | $13.99 | $1,496.93 | −0.6% | |
Quang X. PhamCEO and Chairman | Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/10/02 | 25/10/03 | 500 sh | $14.13 | $7,065 | −0.2% |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/09/29–25/10/01 | 25/10/01 | 1,800 sh2 trades | $13.99avg. | $25,183 | −9.5% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/09/29–25/10/01 | 25/10/01 | 1,300 sh2 trades | $14.01avg. | $18,213 | −0.6% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/09/24–25/09/25 | 25/09/26 | 12,400 sh2 trades | $14.04avg. | $174,145 | −39.6% | |
Cadrenal TherapeuticsCVKD | Open-market sale10b5-1 plan | 25/09/24–25/09/25 | 25/09/26 | 9,371 sh2 trades | $14.06avg. | $131,779.29 | −4.4% |